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The aim of the current letter is to discuss the emerging
issue of breast cancer (BC) metastatic to bone. Bone is the
first metastatic site in [50 % of patients affected by BC.
Symptomatic bone metastases (BMs) account for 20–40 %
of initially diagnosed metastatic BC, and 70 % of recur-
rences or previous bone metastatic BCs develop further
skeletal lesions [1, 2]. Despite the high incidence of BC,
advanced systemic therapies have improved patient’s sur-
vival, thus increasing new diagnoses of BMs. Spine and
proximal femur are the most common locations of sec-
ondary lesions [3]. BMs are the major cause of morbidity in
BC patients, being in 75 % of cases responsible for
intractable pain and skeletal related events (SREs), such as
pathological fractures (in 4–7 % of patients), spinal cord
compression, hypercalcemia, anemia, and may be consid-
ered as a new emergency with high social and healthcare
costs. Peculiar to BC metastatic to bone, is that patients
usually show longer life expectancy after occurrence of
BMs; moreover, bisphosphonates have significantly chan-
ged the natural history of BMs by reducing SREs, so the
majority of patients now live with BMs for several years
(5-year survival rate [20 % with multiple BMs, 40 % if
solitary lesion) [1–3]. An interdisciplinary, patient-cus-
tomized treatment protocol is widely accepted and per-
formed in dedicated multi-professional care centers called
‘‘Breast Units’’ that aim not simply to provide palliative
care, but to guarantee a long survival until complete
remission in selected cases. However, once metastatic
disease develops, medical treatment resistance is com-
monly seen and radiotherapy alone does not prevent
fractures or neurologic complications in numerous cases,
although fractures due to breast BMs respond more
favorably to surgical treatment than do fractures secondary
to other primary tumors [2]. Thus, BC–BMs represent a
major orthopedic issue and multidisciplinary management
needs the participation of the orthopedic surgeon as well as
the oncologist and radiotherapist. Treatment options and
surgical strategies for BMs in general are widely assessed
in several reports and guidelines [4, 5]. The aim of ortho-
pedic treatment is to achieve improvement of the patient’s
survival and quality of life through pain reduction and early
restoration of function. In addition to medical therapies and
adjuvant radiation, the role of orthopedic intervention is
essential, especially for BMs from BC, and theoretically
valuable for every clinical presentation. Patients affected
by breast cancer with poor life expectancy (\3 months),
without SREs or with a pathological fracture of a non-
weightbearing bone, may be initially treated non-opera-
tively (bisphosphonates, analgesics, use of collars, corsets).
Absolute indications for surgery are impending or com-
plete fractures of long bones and pelvic girdle, or un-
treatable pain, instability and spinal compression [4].
Surgical options vary greatly depending on several prog-
nostic factors (Table 1). Operative options for long-bone
fractures include intramedullary nailing, plate-screw fixa-
tion, conventional or mega-prosthetic reconstruction,
eventually in combination with bone cement and other
local adjuvants. With spine involvement, decompression
alone or additional instrumentation and partial vertebral
resection can be performed [3–5]. Minimally invasive and
percutaneous treatments with few side effects and com-
plications, such as radiofrequency ablation, cementoplasty,
cryoplasty, electrochemotherapy, and MRI-guided focused
ultrasound surgery are indicated for patients with no risk of
fracture and poor prognosis, while in the case of a solitary
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lesion and positive prognostic factors, surgery should be
more aggressive and a wide total tumor resection should be
performed.
In conclusion, the epidemiological and clinical impact
of BC is remarkable, and it is clear in the scientific com-
munity that BC–BM is a unique model for studying bone
metastasis. In this context, dedicated orthopedic evidence-
based recommendations exclusively for BC–BMs is
required.
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Table 1 Prognostic factors for BC metastatic to bone
Dimension, histotype, grading of primary tumor
Disease-free interval
First metastasis organs
Estrogen and progesterone receptor status, Her2
Resistance to systemic therapies
Solitary or multiple skeletal lesions
Type of lesions (mixed, lytic, sclerotic)
Skeletal localization
Asymptomatic or symptomatic bone disease (SREs)
Risk of pathological fracture (impending or complete)
Radiation sensitivity
Concomitant non-skeletal metastases
ECOG performance status (Karnofsky score)
Estimated life expectancy above or below 6 months
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